What is the most recent FDA action against Chiesi USA, Inc.?

The most recent FDA event Argus HQ has on file for Chiesi USA, Inc. is dated 2026-07-22, with a severity rating of "high" in Argus HQ's classification. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Does Argus HQ track new FDA actions for Chiesi USA, Inc. automatically?

Yes. Argus HQ ingests FDA sources daily, including FDA warning letters, recalls, drug and biologic approvals, and Form 483 inspection observations. When a new FDA action linked to Chiesi USA, Inc. is observed, this page's event count and history update automatically.

How many FDA actions does Argus HQ track for Chiesi USA, Inc.?

1 total: 0 warning letters, 1 recall, 0 approval records, and 0 Form 483 inspection citations.

What is the most recent FDA action on file for Chiesi USA, Inc.?

July 22, 2026. Argus HQ ingests new FDA enforcement records daily.

Regulatory Record: Chiesi USA, Inc.

FDA action counts

Total FDA actions	1
Warning letters	0
Recalls	1
Approval records	0
Form 483 inspection citations	0
Most recent action	July 22, 2026

In short: Argus HQ has recorded 1 FDA events for Chiesi USA, Inc.: 0 warning letters, 1 recalls, 0 approvals, and 0 inspection 483 observations. These events span from 2026-07-22 to 2026-07-22. The most severe rating Argus HQ has assigned across this history is "high". Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.

Enforcement history

On 2026-07-22, Argus HQ recorded an FDA recall for Chiesi USA, Inc., rated "high" severity in Argus HQ's classification: Chiesi USA, Inc. — Class II recall: CLEVIPREX (clevidipine injectable emulsion) 50 mg/100 mL (0.5 mg/mL), 10 Single…. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.

Risk pattern analysis

Argus HQ analysis — not an FDA finding

This section is Argus HQ analysis, not an FDA finding. Chiesi USA, Inc. has 1 FDA event on file. A pattern across multiple FDA touchpoints does not by itself establish that any specific product currently poses a risk; it reflects only the frequency of FDA engagement with this company as recorded in Argus HQ's database. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ does not independently verify FDA's underlying findings; this page summarizes what FDA has published and links back to the original FDA source for each event. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Frequently asked questions

What is the most recent FDA action against Chiesi USA, Inc.?: The most recent FDA event Argus HQ has on file for Chiesi USA, Inc. is dated 2026-07-22, with a severity rating of "high" in Argus HQ's classification. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
Does Argus HQ track new FDA actions for Chiesi USA, Inc. automatically?: Yes. Argus HQ ingests FDA sources daily, including FDA warning letters, recalls, drug and biologic approvals, and Form 483 inspection observations. When a new FDA action linked to Chiesi USA, Inc. is observed, this page's event count and history update automatically.
How many FDA actions does Argus HQ track for Chiesi USA, Inc.?: 1 total: 0 warning letters, 1 recall, 0 approval records, and 0 Form 483 inspection citations.
What is the most recent FDA action on file for Chiesi USA, Inc.?: July 22, 2026. Argus HQ ingests new FDA enforcement records daily.

Every FDA action tied to this company, the week it happens.

Free weekly briefing. Real-time alerts on paid plans.

Chiesi USA, Inc. — Class II recall: CLEVIPREX (clevidipine injectable emulsion) 50 mg/100 mL (0.5 mg/mL), 10 Single… →

Compare with

Two different companies merged onto this page by mistake? Or a name variant missing? Tell us — corrections@argushq.ai

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Verified from FDA.gov · Last updated: Jul 22, 2026

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2026). Regulatory Record: Chiesi USA, Inc.. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/company/chiesi-usa-inc

MLA

"Regulatory Record: Chiesi USA, Inc.." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/company/chiesi-usa-inc.

Chicago

Argus HQ Research. "Regulatory Record: Chiesi USA, Inc.." Digital Empire Holdings LLC. Accessed July 28, 2026. https://argushq.ai/company/chiesi-usa-inc.

BibTeX

@misc{argushq_argushq_ai_company_chiesi_usa_inc_2026,
  title = {Regulatory Record: Chiesi USA, Inc.},
  author = {{Argus HQ Research}},
  year = {2026},
  publisher = {Digital Empire Holdings LLC},
  url = {https://argushq.ai/company/chiesi-usa-inc},
  note = {Accessed: July 28, 2026}
}

Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗